News ImmuneRegen NewsImmuneRegen BioSciences Closes Round of FundingNovember 02, 2004 4:07:00 PM ET SCOTTSDALE, Ariz., Nov. 2 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that it recently completed a round of equity funding in the amount of two million four hundred fifty thousand dollars with New York investment bank, Joseph Stevens & Company, Inc. The capital is slated to be utilized in the ongoing development of ImmuneRegen BioSciences, Inc.'s compound Homspera, which is proprietary to many areas of health concern. ImmuneRegen BioSciences, Inc. is a wholly owned subsidiary of IR BioSciences Holdings, Inc. Additionally, the capital shall fund the initiation and completion of ImmuneRegen's final study for treatment of Acute Radiation Sickness (ARS) currently under the direction of the FDA. The CEO of ImmuneRegen BioSciences, Michael Wilhelm, expressed the importance of the Joseph Stevens closing: "This capital comes at an important time for our growth, and will enable us to move forward at an accelerated pace on our ARS application. Additionally, the funding will provide means to continue expansion of applications within our pipeline." About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|